Clinical Trial Results:
            PPAR Alpha (LY518674): a Phase 2 Dose-Response Study to Evaluate the Blood Pressure-Lowering Effect in Essential Hypertension
    
|     Summary | |
|     EudraCT number | 2005-004966-17 | 
|     Trial protocol | SE | 
|     Global completion date | 
                                    03 Nov 2006
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    02 Dec 2018
                             | 
|     First version publication date | 
                                    02 Dec 2018
                             | 
|     Other versions | |
|     Summary report(s) | EMBH Summary Results | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
